Baxter International Inc.
Analysis
Two quarters of missed guidance and a dividend cut to almost nothing, then a raise in Q2 2026: the repair is starting to show in the numbers, but the recovery is still second-half weighted and assumed rather than proved. How much of the second-half margin gain comes from cost cuts rather than volume?
- Q2 2026 was the first quarter the turnaround showed up in the numbers.
Every division grew and management raised full-year guidance, after two quarters of misses. Even without a one-off tariff refund, the quarter beat on operations — the first evidence the cost cuts and new operating model are landing.
- Balance-sheet repair is nearly done, and that changes what Baxter can do next.
The dividend was cut to a penny a share to speed debt paydown, and free cash flow turned positive after a year of near-zero. Once net debt hits the roughly 3x target, Baxter can fund small acquisitions again instead of repaying debt. How much of the debt paydown came from asset sales rather than cash flow?
- The recovery is back-half weighted and leans on things Baxter cannot control.
Guidance assumes the Novum pump stays off the market all year, injectables stay short, and hospitals keep conserving IV fluids. Most of the expected gain is ordinary second-half volume, so if it does not show up there is no fallback.
- Broad participation across divisionsThe bull case is that demand improved everywhere at once rather than in one division, so the growth reflects the portfolio and not a single product or a soft comparison.
- Balance sheet repairRising cash generation and a smaller debt load give management room to reinvest in products and make small acquisitions once the leverage target is met.
- Cost-driven margin recoveryCost cuts already taken and the sale of high-cost inventory give a scheduled path to better margins, so profit depends more on internal action than on market growth.
- Pump hold lasting the yearThe bear case is that the pump fix takes so long that hospital customers switch suppliers, and the guidance assumes the lost revenue never returns this year.
- Smaller IV fluids marketHospitals now use less IV fluid than before the hurricane, and management has stopped waiting for a rebound, shrinking a large and long-standing revenue base.
- Pharma supply and mixInjectables cannot be shipped in full because of a contract manufacturer and a shift toward IV push, and the fastest-growing pharma business earns a thinner margin.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Sale | ≥$15K | Jul 23 | Sep 22 |
Donald Trump Republican · Executive | Purchase | ≥$1K | May 18 | Jul 1 |
Donald Trump Republican · Executive | Sale | ≥$1K | May 15 | Jul 1 |
Ro Khanna Democratic · House · CA-17 | Purchase | ≥$1K | May 27 | Jun 9 |
Ro Khanna Democratic · House · CA-17 | Purchase | ≥$1K | May 15 | Jun 9 |
Congressional trading data provided by QuiverQuant
How Baxter International turned $11.2B of revenue into $3.4B of gross profit.
| Revenue | ||
|---|---|---|
| Medical Products And Therapies | $5.3B | ▲ 1.77% YoY |
| Healthcare Systems and Technologies | $3.1B | ▲ 4.07% YoY |
| Pharmaceuticals | $2.5B | ▲ 3.40% YoY |
| Total revenue | $11.2B | |
| Gross profit | $3.4B | 30.1% |